1U5.F WAVE LIFE SCIENCES LTD.
- Market cap
- EUR 969M
- P/E
- -
- P/B
- 1.63x
- ROE
- -52.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1U5.F undervalued?
Graham numberThe Graham number of WAVE LIFE SCIENCES LTD. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
WAVE LIFE SCIENCES LTD. fundamental analysis
No fundamental analysis for WAVE LIFE SCIENCES LTD. yet.
WAVE LIFE SCIENCES LTD. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About WAVE LIFE SCIENCES LTD.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver…
Full company profileWAVE LIFE SCIENCES LTD. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
WAVE LIFE SCIENCES LTD. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 41.0M | 3.65M | 113M | 108M | 42.7M | 71.6M |
| Operating Income | -127M | -163M | -68.0M | -110M | -215M | -228M |
| EBITDA | - | -153M | -58.8M | -102M | -207M | -219M |
| Net Income | -122M | -162M | -57.5M | -97.0M | -204M | -210M |
| EPS | -2.04 | -1.86 | -0.48 | -0.63 | -1.09 | -1.06 |
| Balance Sheet | ||||||
| Total Assets | 207M | 146M | 275M | 352M | 638M | 508M |
| Total Liabilities | 175M | 191M | 235M | 143M | 120M | 106M |
| Shareholders' Equity | 32.5M | -45.1M | 39.6M | 210M | 518M | 402M |
| Cash & Short-term Investments | 151M | 88.5M | 200M | 302M | 602M | 197M |
| Cash Flow | ||||||
| Operating Cash Flow | -89.0M | -128M | -19.4M | -151M | -187M | -231M |
| Capital Expenditure | 560K | 1.36M | 1.12M | 938K | 718K | 1.78M |
| Free Cash Flow | -89.6M | -129M | -20.5M | -152M | -188M | -233M |
| Ratios | ||||||
| ROE | -376.2% | - | -145.1% | -46.3% | -39.4% | -52.2% |
| ROA | -59.1% | -110.5% | -20.9% | -27.5% | -32.0% | -41.3% |
| Net Profit Margin | -298.4% | -4,434.7% | -50.8% | -89.6% | -478.3% | -293.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
WAVE LIFE SCIENCES LTD. dividends
WAVE LIFE SCIENCES LTD. has not paid dividends in the last 5 fiscal years.
Who owns WAVE LIFE SCIENCES LTD.
- Insiders 15.51%
- Institutions 84.50%
- Public & others 0.00%
- Shares outstanding 197M
- Free float 94.6M
WAVE LIFE SCIENCES LTD. company profile
- Company name
- WAVE LIFE SCIENCES LTD.
- Ticker
- 1U5.F
- ISIN
- SG9999014716
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 317
- Fiscal year end
- December
- Address
- 733 Concord Avenue, Cambridge, MA, United States, 02138
- Phone
- 617 949 2900
- Website
- wavelifesciences.com
About WAVE LIFE SCIENCES LTD.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
WAVE LIFE SCIENCES LTD. management
10- Dr. Paul B. Bolno M.B.A., M.D.President, CEO & Director · born 1974
- Dr. Gregory L. Verdine Ph.D.Founder & Director · born 1959
- Mr. Kyle B. Moran CFACFO & Principal Accounting Officer · born 1971
- Dr. Chandra Vargeese Ph.D.Chief Technology Officer · born 1961
- Dr. Christopher Francis Ph.D.Senior VP of Corporate Development & Head of Emerging Areas · born 1978
- Dr. Erik Ingelsson M.D., Ph.D.Chief Scientific Officer
- Ms. Kate RauschHead of Investor Relations
- Ms. Linda Rockett J.D.Senior VP & General Counsel
- Ms. Daryn LewisSenior VP & Head of Human Resources
- Dr. Sridhar Vaddeboina M.B.A., Ph.D.Senior Vice President of Chemistry, Manufacturing & Controls